KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Debt to Equity (2016 - 2020)

Historic Debt to Equity for Nektar Therapeutics (NKTR) over the last 10 years, with Q1 2020 value amounting to $0.39.

  • Nektar Therapeutics' Debt to Equity rose 15922.04% to $0.39 in Q1 2020 from the same period last year, while for Mar 2020 it was $0.39, marking a year-over-year increase of 15922.04%. This contributed to the annual value of $0.36 for FY2019, which is 14887.62% up from last year.
  • According to the latest figures from Q1 2020, Nektar Therapeutics' Debt to Equity is $0.39, which was up 15922.04% from $0.36 recorded in Q4 2019.
  • In the past 5 years, Nektar Therapeutics' Debt to Equity registered a high of $72.16 during Q2 2017, and its lowest value of -$880.47 during Q1 2016.
  • Its 5-year average for Debt to Equity is -$46.96, with a median of $0.17 in 2019.
  • As far as peak fluctuations go, Nektar Therapeutics' Debt to Equity tumbled by 5455195.53% in 2016, and later soared by 126766.84% in 2017.
  • Quarter analysis of 5 years shows Nektar Therapeutics' Debt to Equity stood at $2.76 in 2016, then grew by 1.06% to $2.79 in 2017, then plummeted by 94.85% to $0.14 in 2018, then skyrocketed by 148.88% to $0.36 in 2019, then increased by 9.71% to $0.39 in 2020.
  • Its last three reported values are $0.39 in Q1 2020, $0.36 for Q4 2019, and $0.17 during Q3 2019.